Could a virus injection stop oral cancer before it starts?
NCT ID NCT06623110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new immune therapy called RP2, made from a modified herpes virus, to treat high-risk oral precancerous conditions and prevent them from turning into oral cancer. The therapy is injected directly into the lesion. The trial will enroll 25 people and look at safety, tolerability, and how well the lesions shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RP2 (a genetically modified live herpes simplex virus-1 strain)
- What this could lead to
- If successful, this could provide a new way to prevent oral cancer in people with high-risk precancerous lesions.
- What could go wrong
- This is a small, early-phase trial (25 people) testing safety and effectiveness. The virus-based therapy may cause side effects, and it is not yet proven to prevent cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK ORAL PRECANCEROUS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States